ASCO 2023

ADC revolution: How can the new results be integrated in clinical practice? Which studies are in sight and which ones do we need in the future?

Sonia trial: How does the new data change clinical practice - or does it at all? Insights from Italy, United States and Germany.

Discussions and controversies on social-media: what is the impact of science-twitter discussions on the everyday practice in oncology?

CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe

Expanding CDK4/6i therapy in EBC: How to select patients for the right therapy?

CDK4/6 inhibitors in EBC: Amazing data, but longer follow up needed!

PART2: Trying to understand optimal therapy for pre-menopausal women - promising results, but still long way to go!

PART1: How to de-escalate chemotherapy? What is the best strategy to identify patients who don´t need chemotherapy?

New data on Ribocilib in adjuvant setting EBC: What does it change immediately, what changes are expected in the future? Perspectives from Europe and Northern America

Data from Meta-Analyses of almost 15k Patients: Who benefits from ovarian function suppression?

Chemotherapy de-escalation in HER2+ patients: Consequences of the PHERGain data on daily practice?!

Checkpoint inhibition in endometrial cancer: new therapy algorithms needed

Young patients benefit from ovarian suppression

More CDK4/6 options for EBC patients

Palbociclib after Palbociclib might not be the best option

A challenge for clinical management

Analyses of ctDNA in PENELOPE-B: Test methods are increasingly accurate

Discussions on CDK4/6 inhibitors in EBC

SOC of ovarian ablation confirmed in meta-analysis.

Ribociclib has arrived in the adjuvant setting

1/3 of patients with HER2+ in future without chemotherapy?

Chemo-immunotherapeutic signals especially in HER2low possibly predictive of chemotherapy response in EBC

TILs are prognostic but not predictive in HER2+ EBC

10 years update on ShortHER

White blood cells with increasing prognostic relevance? Data from the GeparNuevo Study

De-escalation of CT for early BC

First data with adjuvant ribociclib

TILs subtypes are associated with clinical features and prognosis in HR+/HER2- BC

Ovarian function - Ovarian suppression not necessary in young patients?

My EBC highlights from ASCO23

From PENELOPE-B to SURVIVE

PHERGain opens the possibility to avoid chemotherapy in HER2+ breast cancer

TILs in HER2+ disease - prognostic, but not enough to deescalate

Practice changing or not quite yet?

Tumor-informed ctDNA likely prognostic for relapse in ER positive and HER2 negative EBC

Another proof of efficacy of immunotherapy in advanced TNBC

Response adapted, chemotherapy-free option in HER2+ EBC

Can we preserve our patients form chemotherapy?

Ribociclib improves iDFS

Early follow-up shows clear benefit

1/3 der Patientinnen mit HER2+ zukünftig ohne Chemotherapie?

SOC der ovarialen Ablation in der Metaanalyse bestätigt

Tumor-informed ctDNA wahrscheinlich prognostisch für einen Rückfall beim ER positive und HER2 negative eBC

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen der Chemotherapie

Ovar Funktion - Ovarielle Supression verzichtbar bei jungen Patientinnen?

Kolejny dowód na skuteczność immunoterapii w zaawansowanym raku trójujemnym

TILs Subtypen sind assoziiert mit klinischen Merkmalen und Prognose beim HR+/HER2- BC

Palbociclib después de Palbociclib podría no ser la mejor opción

Eine Herausforderung für viele Patienten, wenig Doktoren

Eine Herausforderung für das klinische Management

Response adaptierte, Chemotherapie-freie Option beim HER2+ eBC

Czy wystarczy, aby zmienić standardy?

PHERGain abre la posibilidad de evitar la quimioterapia en el cáncer de mama HER2+

TILs w rakach HER2+ - znaczenie rokownicze, ale nie droga do deeskalacji leczenia

Primele date cu ribociclib adjuvant

TILs sind prognostisch aber nicht prädiktiv beim HER2+ eBC

NATALEE nicht überraschend aber überzeugend positiv

I miei punti salienti di ASCO23

Von PENELOPE-B zur SURVIVE

Continued OS benefit for Sacituzumab Govitecan

What is the optimal therapie sequence for HR+ MBC patients?

Molecular imaging for endocrine responsivness

Updates on ADCs in metastatic breast cancer

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

E-Health Applications in Oral Cancer Therapy

The start of precision medicine in HR+ breast cancer

Aggiornamenti sugli ADC nel carcinoma mammario metastatico

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo studio PALMIRA

Mises à jour sur les ADC dans le cancer du sein métastatique

Update ADC efficacy

The value of eHealth

CDK4/6 Sequencing? ESR-1 not ready for prime time? Palbo rechallenge?

CDK4/6i in first line and beyond & Biomarkers

AI for prediction in local prostate carcinoma

Reassuring real-world data!

Metastasis-directed for prostate cancer

PAPR-inhibitors: Patient-selection matters!

TALAPRO-2: Results and controversies

Part2: Important update on testosterone-recovery

PRL-02: Intramuscular arbiraterone

PSA nadir 6 month after Radiotherapy is strong prognostic marker for survival

PEACE 1 - results and controversies

Intensified or de-intensified therapy in mHSPC

LuPARP combination study: LuPSMA and Olaparib in mCRPC

ARASEC: ADT + Daralutamide for mHSPC

Part 1: Important update on testosterone-recovery

Confirming results for PARPi in mCRPC

Over-staging of bone scan compared with PSMA PET/CT

DEAR trial: real-world comparator analyses of ARIs

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

PARP-inhibitors: La selección de pacientes es importante

PSA nadir 6 månader efter radioterapi är en prognostisk markör för överlevnad

Intensifierad eller de-intensifierad behandling vid mHSPC?

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

What is your preferred sequence in 1st line treatment and how you treat after progress?

Triple therapy in mCSPC - which is the ideal partner for radiotherapy? And which patients should received irradiation?

PARPi in PCa: more genetic testing is required as PRO data demand better patient selection

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Q-TWiST in the therapy of aUC

The beginning of a new era in urothelial cancer?!

New standard for MIBC

Enfortumab vedotin + pembrolizumab 1stL in cisplatin-ineligible patients

Extent of lymphadenectomy in cystectomy

First line in cisplatin-ineligible advance urothelial cancer: It´s getting busy out there

FGFR inhibition

New SoC option for metastatic bladder cancer

Targeted therapies in advanced urothelial cancer: The renaissance?!

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Nouvelles options de soins standard pour le cancer de la vessie métastatique

Primera línea en cáncer urotelial avanzado no elegible para cisplatina: Hay mucho trabajo ahí fuera

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El renacimiento?!

Update EV/Pembro, Avelumab Maintenance

The efficacy of FGFR targeting

The efficacy of neo-adjuvant therapy (ddMVAC, Cisplatinum)

Long term follow up in advanced renal cell cancer: Is everything clear, yet?

Non ccRCC: how should we treat patients today?

The impact of microbiome and supplements on therapy efficacy

Primary endpoint not reached: what do we learn from CONTACT-03 results?

Long-term follow-up for IO/TKI in mRCC

Update and take home message of 1st Line mRCC

New standard for 2nd line RCC?

Lenvatinib + pembrolizumab in non-clear cell renal cell carcinoma

News from the adjuvant

1st Line therapy RCC: which combination to choose?

New data non ccRCC

IO rechallenge in mRCC

ADAURA: Osimertinib improves survival in the treatment of EGFRm rNSCLC

The value of perioperative chemo-IO in rNSCLC and the importance of staging

An imperfect analysis, but perfect results

A chemo-free preop. IO strategy?

A new standard of care for operated patients with eGFRmut adenocarcinoma

Adjuvant IO in KRASm patients

OS benefit from EGFR receptor TKI

Induction options in the perioperative setting

EGFR testing necessary in the adjuvant setting

Which should we prefer: neoadjuvant, adjuvant or perioperative chemo/IO?

Confirmation of neoadjuvant immunotherapy

More options in the perioperative setting

Perioperative treatment

Another neoadjuvant chemo/IO option

Role of periopertative IO confirmed

ADAURA - results and controversies

Added benefit of perioperative chemo/IO in stage 2-3b NSCLC

ADAURA - Discussion closed?

CheckMate 9LA: 4‑year clinical update

Adjuvant and neoadjuvant strategies in resectable NSCLC

A new standard of care

Un nouveau standard therapeutique pour les patients opérés d’un adenocarcinome EGFR muté

Que devrions-nous préférer: traitement néoadjuvant, adjuvant ou chimio/IO périopératoire?

ADAURA- discussie gesloten?

Más opciones en el entorno perioperatorio

Stratégies adjuvantes et néoadjuvantes dans le CBNPC résécable

Rolle der periopertativen IO bestätigt

Toegevoegde waarde van periperatief chemo-immuno bij stadium II-IIIB NSCLC

TTF-treatment requires further studies

Sotorasib: clear clinical benefit, but short follow-up time

Does ADC + chemo + IO replace the existing concepts?

Update on KRASG12Cm treatment options - how to proceed?

Pembro + chemo in pts with TKI-resistant EGFRm / Sunvozertinib - a drug for Exon20 insertions

Zorifertinib: an option when osimertinib is not available

ADC + ICI ± Pt-CT in patients with aNSCLC

IO in EGRF positive patients post TKI

CORRELATE - a real world analysis

Stopping treatment is ok

LUNAR: TTF medical device shows OS-benefit, but more information needed

TROP2-ADC shows high response rates in 1L-combination therapy, but safety must be observed

Hyperfractionation - an interestingh concept, but not for every patient

New data from another BiTE

Treatment strategies in SCLC

A positive trial with no impact

More BiTEs, more possibilities

Hyperfractionated radiotherapy for SCLC

Can we incoporate biomarkers in SCLC treatment?

Stratégies de traitement dans le SCLC

Kunnen we biomarkers gebruiken om behandeling te selecteren voor SCLC?

Más BiTEs, más posibilidades

Immune checkpoint inhibitors in malignant mesothelioma

No practice-changing data in mesothelioma, other studies to await

ONCOalert (inclusive patient advocates) consensus on the results of the PROspect trial

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom